# Competitive LC-MS/MS assay to investigate protein metalation dynamics

## TL;DR

A new LC-MS/MS assay reveals how metallodrugs selectively bind to proteins, offering insights for designing better metallodrugs.

## Contribution

A competitive LC-MS/MS assay was developed to study metalation dynamics of metallodrugs in protein mixtures.

## Key findings

- Metallodrugs show metal-dependent selectivity in forming protein adducts.
- Zeise's salt derivative reacts more strongly with sulfur donor atoms than cisplatin.
- Ruthenium compounds prefer N-donor coordination, especially with histidine residues.

## Abstract

Knowledge gaps in the biospeciation of potential metallodrugs may lead to the generalized assumption of their promiscuous reactivity and inherent toxicity, neglecting their pharmaceutical potential. Herein, we developed a rapid and competitive LC-MS/MS assay to determine metalation dynamics of protein mixtures by metallodrugs. Specifically, the time-dependent reactivity of different metallodrugs, based on platinum(ii) (cisplatin, [Pt(ala)(ASA-But)Cl]), ruthenium(ii) ([Ru(HQ)(Cym)Cl], [Ru(NHC)(Cym)Cl2]), and iridium(iii) ([Ir(HQ)(Cp*)Cl], [Ir(NHC)(Cp*)Cl2]), towards an equimolar protein mixture was investigated. The assay revealed metal-dependent selectivity of adduct formation and subsequent deactivation by cellular detoxifying nucleophiles, e.g. glutathione (GSH). Online top-down fragmentation further enabled the localization of binding sites of metallodrugs on proteins in the same run, which could be directly related to complex speciation behaviour. The reactivity of Zeise's salt derivative [Pt(ala)(ASA-But)Cl] (ala = l-alanine; ASA-But = but-3-en-1-yl 2-acetoxybenzoate) with sulfur donor atoms was found to exceed all investigated compounds, including cisplatin. Ruthenium compounds preferred N-donor coordination, which resulted in a strong affinity towards histidine residues. Protein adducts of the somewhat redox-active iridium compounds were quickly transformed into stable adducts with detoxifying nucleophiles, especially with GSH. This model system provides further evidence that metallodrug reactivity is more selective in competitive settings, as would be anticipated from exposure to single biomolecules. This implies that the intracellular selectivity of metallodrugs can be chemically tuned and that this aspect may be accounted for in future metallodrug design. Such design strategies will be supported by expanding the present competitive assay to more complex systems that better mimic physiological intra- and extracellular tumour microenvironments.

Speciation analysis reveals selective binding in competitive assays. Metal-dependent binding selectivities may be exploited to guide future metallodrug design.